Abstract

In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call